The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence
Open accessAbstract
Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen, progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for more than 15–20% of all breast cancers and is of particular research interest as it is therapeutically challenging mainly because of its low response to therapeutics and highly invasive nature. The non-availability of specific treatment options for TNBC is usually managed by conventional therapy, which often leads to relapse. The focus of this review is to provide up-to-date information related to TNBC epidemiology, risk factors, metastasis, different signaling pathways, and the pathways that can be blocked, immune suppressive cells of the TNBC microenvironment, current and investigation therapies, prognosis, and the role of artificial intelligence in TNBC diagnosis. The data presented in this paper may be helpful for researchers working in the field to obtain general and particular information to advance the understanding of TNBC and provide suitable disease management in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,790
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Additionally, these cancers have characteristic metastatic patterns and poor prognosis (Dent et al., 2007).”
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“Considering the therapeutic potential of the PD-L1 pathway, several immunotherapies have been explored, and atezolizumab combined with nanoparticle albumin-bound paclitaxel has been approved by the US FDA as the fi rst-line therapy in 2019 (Schmid et al., 2018).”
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“Furthermore, Wnt inhibitors can destroy drug-resistant cells and cancer stem cells (Dean et al., 2005).”
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Kyu, H. H., Bachman, V. F., Alexander, L. T., Mumford, J. E., Afshin, A., Estep, K., Veerman, J. L., Delwiche, K., Iannarone, M. L., Moyer, M. L., et al. (2016) · BMJ · doi:10.1136/bmj.i3857 · Cited by 1,272
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.43 · Cited by 1,115
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., & Adams, R. H. (2009) · Cell · doi:10.1016/j.cell.2009.03.025 · Cited by 1,107
Fiolet, T., Srour, B., Sellem, L., Kesse-Guyot, E., Allès, B., Méjean, C., Deschasaux, M., Fassier, P., Latino-Martel, P., Beslay, M., et al. (2018) · BMJ · doi:10.1136/bmj.k322 · Cited by 1,057
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
Protani, M., Coory, M., & Martin, J. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0990-0 · Cited by 962
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Genetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 801
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 631
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“It has been revealed that OMP-18R5 antibody targets Frizzled receptors to diminish tumor cell proliferation in colon, lung, breast, and pancreatic tumors (Gurney et al., 2012).”
Intracellular Cleavage of Notch Leads to a Heterodimeric Receptor on the Plasma Membrane
Blaumueller, C. M., Qi, H., Zagouras, P., & Artavanis-Tsakonas, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80336-0 · Cited by 614
Deepak, K. G. K., Vempati, R., Nagaraju, G. P., Dasari, V. R., S., N., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 614
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Mechanisms Governing Metastatic Dormancy and Reactivation
Giancotti, F. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.029 · Cited by 586 · cited 2×
“Successful emergence from dormancy is the result of further evolution of surviving disseminated tumor cells by accumulating molecular changes as well as via permissive interactions with the tumor microenvironment (Giancotti, 2013).”
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
Weijzen, S., Rizzo, P., Braid, M., Vaishnav, R., Jonkheer, S. M., Zlobin, A., Osborne, B. A., Gottipati, S., Aster, J. C., Hahn, W. C., et al. (2002) · Nature Medicine · doi:10.1038/nm754 · Cited by 550
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
Genetics of breast cancer: a topic in evolution
Shiovitz, S., & Korde, L. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv022 · Cited by 525
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol
Hoover, R. N., Hyer, M., Pfeiffer, R. M., Adam, E., Bond, B., Cheville, A. L., Colton, T., Hartge, P., Hatch, E. E., Herbst, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013961 · Cited by 444
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 430
The Relationship of Mammographic Density and Age: Implications for Breast Cancer Screening
Checka, C. M., Chun, J. E., Schnabel, F. R., Lee, J., & Toth, H. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.10.6049 · Cited by 422
Notch signaling: An emerging therapeutic target for cancer treatment
Yuan, X., Wu, H., Xu, H., Xiong, H., Chu, Q., Yu, S., Wu, G. S., & Wu, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.048 · Cited by 402
(2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70301-2 · Cited by 399
Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.004 · Cited by 396
Giordano, S. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1707939 · Cited by 390
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384 · cited 1×
“Research regarding the use of immune checkpoint inhibitor(s) either alone as a single agent or in combination therapy is ongoing (Adams et al., 2019).”
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J., Malone, C., McLaughlin, R., & Kerin, M. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 374
Cigarette smoking and the risk of breast cancer in women: a review of the literature.
Terry, P., & Rohan, T. E. (2002) · PubMed · Cited by 361
Prenatal Diethylstilbestrol Exposure and Risk of Breast Cancer
Palmer, J. R., Wise, L. A., Hatch, E. E., Troisi, R., Titus-Ernstoff, L., Strohsnitter, W., Kaufman, R., Herbst, A. L., Noller, K. L., Hyer, M., et al. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0109 · Cited by 347
Epidemiology of Triple-Negative Breast Cancer: A Review
Howard, F. M., & Olopade, O. I. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000500 · Cited by 338
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Hayashi, K., Nakamura, M., Sakamoto, W., Yogo, T., Miki, H., Ozaki, S., Abe, M., Matsumoto, T., & Ishimura, K. (2013) · Theranostics · doi:10.7150/thno.5860 · Cited by 329
Liang, R., Liu, L., He, H., Chen, Z., Han, Z., Luo, Z., Wu, Z., Zheng, M., Ma, Y., & Cai, L. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.051 · Cited by 300
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Chan, S. M., Weng, A. P., Tibshirani, R., Aster, J. C., & Utz, P. J. (2007) · Blood · doi:10.1182/blood-2006-08-039883 · Cited by 281
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00148-7 · Cited by 275
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266 · cited 4×
“(Xie et al., 2016; Medina et al., 2020). and improving free survival rate of TNBC patients (Reis-Filho and Tutt, 2008; Yu and Di, 2017).”
InfluentialAnticancer Mechanisms of Cannabinoids
Velasco, G., Sánchez, C., & Guzmán, M. (2016) · Current Oncology · doi:10.3747/co.23.3080 · Cited by 265
Breast cancer statistics and markers
Kondapalli, K., Donepudi, M., Amos, S. J., & Venkanteshan, P. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.137927 · Cited by 252
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Predictors of distress in female breast cancer survivors: a systematic review
Syrowatka, A., Motulsky, A., Kurteva, S., Hanley, J. A., Dixon, W. G., Meguerditchian, A. N., & Tamblyn, R. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4290-9 · Cited by 230
Links between Alcohol Consumption and Breast Cancer: A Look at the Evidence
Liu, Y., Nguyen, N., & Colditz, G. A. (2015) · Women's Health · doi:10.2217/whe.14.62 · Cited by 229
Iyengar, N. M., Arthur, R., Manson, J. E., Chlebowski, R. T., Kroenke, C. H., Peterson, L., Cheng, T.-Y. D., Feliciano, E. C., Lane, D., Luo, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5327 · Cited by 226
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.007 · Cited by 226
Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses.
Brandes, L. J., Arron, R. J., Bogdanovic, R. P., TONG, J. J., Zaborniak, C. L., Hogg, G. R., Warrington, R. C., Fang, W., & LaBella, F. S. (1992) · PubMed · Cited by 211
Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X.-F., Bencsath, K. P., Panageas, K. S., Chin, J., Hudis, C. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626298 · Cited by 205
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Alcohol Use and Breast Cancer: A Critical Review
Shield, K. D., Soerjomataram, I., & Rehm, J. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13071 · Cited by 204
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Zeichner, S. B., Terawaki, H., & Gogineni, K. (2016) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s32783 · Cited by 196
Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up
Zhang, X., Tworoger, S. S., Eliassen, A. H., & Hankinson, S. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2391-z · Cited by 189
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Wang, X., Osada, T., Wang, Y., Yu, L., Sakakura, K., Katayama, A., McCarthy, J. B., Brufsky, A., Chivukula, M., Khoury, T., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq343 · Cited by 188
The Effect of Curcumin on Breast Cancer Cells
Liu, D., & Chen, Z. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.2.133 · Cited by 185
Castelló, A., Pollán, M., Buijsse, B., Ruiz, A., Casas, A. M., Baena-Cañada, J. M., Lope, V, Antolín, S., Ramos, M., Muñoz, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.434 · Cited by 182
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Yu, T., Department of Breast Surgery, F. U. S. C. C., Di, G., & Department of Oncology, S. M. C. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.03.10 · Cited by 179
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 178
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
Eccles, S. A. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113396se · Cited by 176
Vitamin D, Calcium, and Breast Cancer Risk: A Review
Cui, Y., & Rohan, T. E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0075 · Cited by 176
Cooney, C. A., Jousheghany, F., Yao-Borengasser, A., Phanavanh, B., Gomes, T., Kieber-Emmons, A. M., Siegel, E. R., Suva, L. J., Ferrone, S., Kieber-Emmons, T., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2895 · Cited by 175
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Barcellos‐Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 171
The paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 167
Palomero, T., Barnes, K. C., Real, P. J., Glade Bender, J. L., Sulis, M. L., Murty, V. V., Colovai, A. I., Balbin, M., & Ferrando, A. A. (2006) · Leukemia · doi:10.1038/sj.leu.2404258 · Cited by 166
Recent Progress on NIR-II Photothermal Therapy
Zhang, Y., Zhang, S., Zhang, Z., Ji, L., Zhang, J., Wang, Q., Guo, T., Ni, S., Cai, R., Mu, X., et al. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.728066 · Cited by 165
Menstrual factors in relation to breast cancer risk.
Titus-Ernstoff, L. T., Longnecker, M. P., Newcomb, P. A., Dain, B., Greenberg, E. R., Mittendorf, R. L., Stampfer, M. J., & Willett, W. C. (1998) · PubMed · Cited by 162
Dietary Patterns and Breast Cancer Risk: A Systematic Review
Dandamudi, A., TOMMIE, J., Nommsen‐Rivers, L. A., & Couch, S. C. (2018) · Anticancer Research · doi:10.21873/anticanres.12586 · Cited by 160
Obesity in breast cancer – What is the risk factor?
James, F. R., Wootton, S. A., Jackson, A. A., Wiseman, M. J., Copson, E., & Cutress, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.057 · Cited by 152
Bioactivity of Turmeric-derived Curcuminoids and Related Metabolites in Breast Cancer
Wright, L. E., Frye, J. B., Gorti, B., Timmermann, B. N., & Funk, J. L. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319340013 · Cited by 140
Effects of Alcohol on the Endocrine System
Rachdaoui, N., & Sarkar, D. K. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.008 · Cited by 139
The prognostic importance of triple negative breast carcinoma
Mersin, H., Yıldırım, E., Berberoğlu, U., & Gülben, K. (2008) · The Breast · doi:10.1016/j.breast.2007.11.031 · Cited by 138
Rhee, J., Han, S., Oh, D., Kim, J. H., Im, S., Han, W., Park, I. A., Noh, D., Bang, Y., & Kim, T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-307 · Cited by 136
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Antón, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-gs3-04 · Cited by 136
Yam, C., Mani, S. A., & Moulder, S. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0095 · Cited by 135
The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Singh, S., Numan, A., Maddiboyina, B., Arora, S., Riadi, Y., Md, S., Alhakamy, N. A., & Kesharwani, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.011 · Cited by 133
Antidepressant Medication Use and Breast Cancer Risk
Cotterchio, M., Kreiger, N., Darlington, G., & Steingart, A. B. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010138 · Cited by 132
Dvl2-Dependent Activation of Daam1 and RhoA Regulates Wnt5a-Induced Breast Cancer Cell Migration
Zhu, Y., Tian, Y., Du, J., Hu, Z., Yang, L., Liu, J., & Gu, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037823 · Cited by 131
Singh, R., Swanner, J., Mims, J., Akman, S., Furdui, C., Torti, S., & Carroll, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80349 · Cited by 130
Hilakivi-Clarke, L. A. (2014) · Breast Cancer Research · doi:10.1186/bcr3649 · Cited by 129
Sharma, A., Paranjape, A. N., Rangarajan, A., & Dighe, R. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0508 · Cited by 121
Nabholtz, J., Abrial, C., Mouret‐Reynier, M., Dauplat, M.-M., Weber, B. E., Gligorov, J., Forest, A. M., Trédan, O., Vanlemmens, L., Petit, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu183 · Cited by 121
Liao, W., Ho, Y. C., Lin, Y.-W., Raj, E. N., Liu, K., Chen, C., Zhou, X.-Z., Lu, K.-P., & Chao, J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.025 · Cited by 121
Obesity and breast cancer: A case of inflamed adipose tissue
Kolb, R., & Zhang, W. (2020) · Cancers · doi:10.3390/cancers12061686 · Cited by 119 · cited 1×
“Epidemiologically, estrogen receptor-positive breast cancer develops in obese women in the postmenopausal period (Kolb and Zhang, 2020).”
Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer
Wang, J., Costantino, J. P., Tan-Chiu, E., Wickerham, D. L., Paik, S., & Wolmark, N. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djhs105 · Cited by 119
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Nofech‐Mozes, S., Trudeau, M., Kahn, H. K., Dent, R. A., Rawlinson, E., Sun, P., Narod, S. A., & Hanna, W. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0295-8 · Cited by 116
Nie, L., Wei, Y., Zhang, F., Hsu, Y.-H. E., Chan, L.-C., Xia, W., Ke, B., Zhu, C., Deng, R., Tang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13105-5 · Cited by 111
Impact of Triple Negative Phenotype on Breast Cancer Prognosis
Kaplan, H. G., & Malmgren, J. A. (2008) · The Breast Journal · doi:10.1111/j.1524-4741.2008.00622.x · Cited by 110
Green tea compounds in breast cancer prevention and treatment
Li, M., Yin, Y.-C., Wang, J., & Jiang, Y.-F. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.520 · Cited by 104
Zhang, Q., Liu, J., Ao, N., Yu, H., Peng, Y., Ou, L., & Zhang, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58134-z · Cited by 104
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas
Annaratone, L., Cascardi, E., Vissio, E., Sarotto, I., Chmielik, E., Sapino, A., Berrino, E., & Marchiò, C. (2020) · Pathobiology · doi:10.1159/000507055 · Cited by 104
Notch3: from subtle structural differences to functional diversity
Bellavia, D., Checquolo, S., Campese, A. F., Felli, M. P., Gulino, A., & Screpanti, I. (2008) · Oncogene · doi:10.1038/onc.2008.230 · Cited by 99
Minimizing second cancer risk following radiotherapy: current perspectives
Ng, J., & Shuryak, I. (2014) · Cancer Management and Research · doi:10.2147/cmar.s47220 · Cited by 98
Radiation therapy for breast cancer: Literature review
Balaji, K., BalajiSubramanian, S., Yadav, P., Radha, C. A., & Ramasubramanian, V. (2016) · Medical dosimetry · doi:10.1016/j.meddos.2016.06.005 · Cited by 97
Epidemiologic issues related to the association between physical activity and breast cancer
Friedenreich, C. M., Thune, I., Brinton, L. A., & Albanes, D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980801)83:3+<621::aid-cncr4>3.0.co;2-a · Cited by 94
Schacht, D. V., Yamaguchi, K., Lai, J., et al. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.13.11553 · Cited by 94
Corda, G., Sala, G., Lattanzio, R., Iezzi, M., Sallese, M., Fragassi, G., Lamolinara, A., Mirza, H., Barcaroli, D., Ermler, S., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4841 · Cited by 88
Targeting the Hedgehog signaling pathway for cancer therapy
Li, Y., Maitah, M. Y., Ahmad, A., Kong, D., Bao, B., & Sarkar, F. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.617367 · Cited by 81
Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz‐Esparza, G. U., González-Delgado, C. A., Cara, F. E., Granados-Principal, S. M., Evans, K. W., Akçakanat, A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.27 · Cited by 78
Antibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million Women
FRIEDMAN, G. D., Oestreicher, N., Chan, J., Quesenberry, C. P., Udaltsova, N. V., & Habel, L. A. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0401 · Cited by 77
Notch signaling: its roles and therapeutic potential in hematological malignancies
Gu, Y., Masiero, M., & Banham, A. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7772 · Cited by 75
Meng, Q., Meng, J., Ran, W., Wang, J., Zhai, Y., Zhang, P., & Li, Y. (2018) · ACS Nano · doi:10.1021/acsnano.7b09210 · Cited by 73
Incorvaia, L., Fanale, D., Bono, M., Calò, V., Fiorino, A., Brando, C., Corsini, L. R., Cutaia, S., Cancelliere, D., Pivetti, A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920975326 · Cited by 70
Kuroda, H., Jamiyan, T., Yamaguchi, R., Kakumoto, A., Abe, A., Harada, O., & Masunaga, A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02652-3 · Cited by 69
Cigarette smoking increases risk for breast cancer in high-risk breast cancer families.
Couch, F. J., Cerhan, J. R., Vierkant, R. A., Grabrick, D. M., Therneau, T. M., Pankratz, V. S., Hartmann, L. C., Olson, J. E., Vachon, C. M., & Sellers, T. A. (2001) · PubMed · Cited by 68
Feng, B., Xu, Z., Zhou, F., Yu, H., Sun, Q., Dangge, W., Tang, Z., Yu, H., Yin, Q., Zhang, Z., et al. (2015) · Nanoscale · doi:10.1039/c5nr03693c · Cited by 66
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 60
Johns, L. E., Jones, M. E., Schoemaker, M. J., McFadden, E. C., Ashworth, A., & Swerdlow, A. J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.359 · Cited by 58
Epidemiology of breast cancer – selected highlights
Cuzick, J. M. (2003) · The Breast · doi:10.1016/s0960-9776(03)00144-9 · Cited by 54
The Functional Role of Notch Signaling in Triple-Negative Breast Cancer
Speiser, J. J., Erşahin, Ç. H., & Osipo, C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00013-7 · Cited by 51
Is There One Key Step in the Metastatic Cascade?
Dujon, A. M., Capp, J., Brown, J. S., Pujol, P., Gatenby, R. A., Újvári, B., Alix‐Panabières, C., & Thomas, F. (2021) · Cancers · doi:10.3390/cancers13153693 · Cited by 50
Vyas, D., Lopez‐Hisijos, N., Gandhi, S., El‐Dakdouki, M. H., Basson, M. D., Walsh, M. F., Huang, X., Vyas, A. K., & Chaturvedi, L. S. (2015) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.10834 · Cited by 46
Diet and risk of breast, endometrial and ovarian cancer: UK Women’s Cohort Study
Dunneram, Y., Greenwood, D. C., & Cade, J. E. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518003665 · Cited by 45
Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care
Singh, S., Numan, A., Agrawal, N., Tambuwala, M. M., Singh, V., & Kesharwani, P. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106417 · Cited by 45
Hsiao, Y.-C., Yeh, M., Chen, Y., Liu, J., Tang, C., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5700 · Cited by 43
Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study
Hill, D. A., Prossnitz, E. R., Royce, M., & Nibbe, A. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224064 · Cited by 43
The critical role of p16/Rb pathway in the inhibition of GH3 cell cycle induced by T-2 toxin
Fatima, Z., Guo, P., Huang, D., Lu, Q., Wu, Q., Dai, M., Cheng, G., Peng, D., Tao, Y., Ayub, M., et al. (2018) · Toxicology · doi:10.1016/j.tox.2018.03.006 · Cited by 42
Artificial Light at Night and Cancer: Global Study
Al-Naggar, R. A., & Anil, S. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.10.4661 · Cited by 38
Suleman, M., Qamar, M. T. U., Saleem, S., Ahmad, S., Ali, S. S., Khan, H., Akbar, F., Khan, W., Alblihy, A., Alrumaihi, F., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.692835 · Cited by 36
Videnros, C., Selander, J., Wiebert, P., Albin, M. C., Plato, N., Borgquist, S., Manjer, J., & Gustavsson, P. (2019) · International Archives of Occupational and Environmental Health · doi:10.1007/s00420-019-01479-4 · Cited by 33
Riaz, M., Ashfaq, U. A., Qasim, M., Yasmeen, E., Qamar, M. T. U., & Anwar, F. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000548 · Cited by 32
Muneer, I., Qamar, M. T. U., Tusleem, K., Rauf, S. A., Hussain, H. M. J., & Siddiqi, A. R. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000727 · Cited by 32
Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
Park, S. R., & Chen, A. P. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.012 · Cited by 31
Alcohol consumption and the risk of breast cancer.
Coronado, G. D., Beasley, J. M., & Livaudais, J. C. (2012) · PubMed · Cited by 31
Sobande, F., Dušek, L., Matějková, A., Rozkoš, T., Laco, J., & Ryška, A. (2015) · PubMed · Cited by 30
Wang, X., Hui, T., Wang, M., Liu, H., Li, R., & Song, Z. (2019) · Oncology Research and Treatment · doi:10.1159/000496548 · Cited by 30
Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation
Muneer, I., Ahmad, S., Naz, A., Abbasi, S. W., Alblihy, A., Aloliqi, A. A., Alkhayl, F. F. A., Alrumaihi, F., Ahmad, S., Bakri, Y. E., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.716735 · Cited by 28
Chang, J.-W., Ding, Y., Qamar, M. T. U., Shen, Y., Gao, J., & Chen, L. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz044 · Cited by 24
Breast cancer family history and allele-specific DNA methylation in the legacy girls study
Wu, H.-C., Do, C., Andrulis, I. L., John, E. M., Daly, M. B., Buys, S. S., Chung, W. K., Knight, J. A., Bradbury, A. R., Keegan, T. H. M., et al. (2018) · Epigenetics · doi:10.1080/15592294.2018.1435243 · Cited by 19
Zheng, H., Chen, C., Wu, X., Chen, J., Sun, S., Jin-zhong, S., Wang, M.-W., & Sun, S. (2015) · Tumor Biology · doi:10.1007/s13277-015-4079-6 · Cited by 12
Metadata
- Authors
- Almansour, N. M.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2022-01-25
- Volume
- 9
- Pages
- 836417-836417
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W4207050061
- Cited by
- 397
- References
- 157
- FWCI
- 27.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.